These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11136375)

  • 21. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A.
    Lindgren A; Wadenvik H; Tengborn L
    Haemophilia; 2002 Sep; 8(5):644-8. PubMed ID: 12199673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients.
    Blanco AN; Peirano AA; Grosso SH; Gennari LC; Bianco RP; Lazzari MA
    Haematologica; 2000 Oct; 85(10):1045-50. PubMed ID: 11025595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
    Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
    Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
    Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
    Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
    Klintman J; Hillarp A; Donfield S; Berntorp E; Astermark J
    Haemophilia; 2013 Jan; 19(1):106-12. PubMed ID: 22762454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.
    Ling M; Duncan EM; Rodgers SE; Street AM; Lloyd JV
    J Thromb Haemost; 2003 Dec; 1(12):2548-53. PubMed ID: 14675091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC; Williams I; Bray GL; Peake IR
    Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII clotting antigen (VIIICAg) in haemophilia measured by two immunoradiometric assays (IRMA) using different antibodies, and the measurement of inhibitors to procoagulant factor VIII (VIIIC) by IRMA.
    Furlong RA; Peake IR; Bloom AL
    Br J Haematol; 1981 Aug; 48(4):643-50. PubMed ID: 6791678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixing-based inhibitor screening in haemophilia A: challenges in interpretation.
    Arshad S; Awasthi NP; Husain N; Neyaz A; Singh A
    Blood Coagul Fibrinolysis; 2019 Dec; 30(8):401-408. PubMed ID: 31644446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
    Houissa B; Mliki ML; Abdelkafi S; Bouslama M; Zaïer M; Mahjoub T; Kortas M; Ghachem L; Yacoub S
    Hamostaseologie; 2003 Aug; 23(3):144-8. PubMed ID: 12923586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
    Miller CH
    Haemophilia; 2018 Mar; 24(2):186-197. PubMed ID: 29446525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of antifactor VIII antibody titre in the presence of emicizumab; Use of chromogenic Bethesda assays.
    Bowyer A; Kitchen S; Maclean R
    Int J Lab Hematol; 2021 Aug; 43(4):O204-O206. PubMed ID: 33764652
    [No Abstract]   [Full Text] [Related]  

  • 38. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K; Nogami K; Shima M
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 40. Porcine factor VIII in the treatment of high-titre inhibitor patients.
    Garvey MB
    Haemophilia; 2002 Jan; 8 Suppl 1():5-8; discussion 28-32. PubMed ID: 11882075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.